About Centro Dr. Lazaro Langer S.R.L
Clinical Trials at Centro Dr. Lazaro Langer S.R.L
During the past decade, Centro Dr. Lazaro Langer S.R.L conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on
average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100%
of trials that started reached the finish line.
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at Centro Dr. Lazaro Langer S.R.L
According to Clinical.Site data, the most researched conditions in "Centro Dr. Lazaro Langer S.R.L" are
"Lung Diseases, Interstitial" (2 trials). Many other conditions were trialed in "Centro Dr. Lazaro Langer S.R.L" in a lesser frequency.
Clinical Trials Intervention Types at Centro Dr. Lazaro Langer S.R.L
Most popular intervention types in "Centro Dr. Lazaro Langer S.R.L" are "Drug" (2 trials). Other intervention types were less common.
The name of intervention was led by "Nintedanib" (2 trials) and "Placebo" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Centro Dr. Lazaro Langer S.R.L
The vast majority of trials in "Centro Dr. Lazaro Langer S.R.L" are
2 trials for "All" genders.
Clinical Trials Status at Centro Dr. Lazaro Langer S.R.L
Currently, there are NaN active trials in "Centro Dr. Lazaro Langer S.R.L".
undefined are not yet recruiting,
undefined are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 2 completed trials in Centro Dr. Lazaro Langer S.R.L,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Centro Dr. Lazaro Langer S.R.L, 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 2 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".